Medical

An intranasal formulation of diazepam being developed by Neurelis for the treatment of acute seizures outside of a hospital setting demonstrated 96% bioavailability compared to the only currently approved treatment, a rectal diazepam gel. The… Read more . . .

A Phase 2b study of Aradigm’s inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchietasis has shown a significant reduction in Pseudomonas aeruginosa colony forming units per gram of sputum (CFUs) over a 28-day treatment… Read more . . .

An article by Johns Hopkins researchers published in the BMJ, the British Medical Journal, suggests that patients using the Respimat tiotropium soft mist inhaler for the treatment of COPD are 52% more likely to die… Read more . . .

At the European Cystic Fibrosis Conference in Hamburg, Germany, Insmed presented data showing that Arikace liposomal amikacin for inhalation improved lung function in CF patients over six cycles of treatment. Each cycle included 28 days… Read more . . .

A Phase 1 clinical trial of an inhaled dry powder formulation of atropine for the treatment of nerve agent poisoning has been completed successfully, according to MicroDose Therapeutx. MicroDose subsidiary MicroDose Defense Products is developing… Read more . . .

GSK and Theravance have announced results for two Phase 3 studies of its ICS/LABA combo DPI Relovair for the treatment of COPD. The product combines fluticasone furoate and vilanterol. The companies said that the studies… Read more . . .

Data presented at the 2011 American Thoracic Society (ATS) meeting by Novartis regarding combined indacaterol and tiotropium therapy for COPD demonstrate that the LABA/LAMA combination produced greater improvement in lung function than tiotropium alone. Novartis’s… Read more . . .